API Solutions


Dark Blue Asymchem Long Graphic

From Laboratory to GMP Production

Asymchem’s oligonucleotide technology capabilities provide clients with full services in drug substance, from process development through oligonucleotide GMP manufacturing, and drug product, from pre-formulation development through fill-finish. The process chemistry, analytical, formulation, and regulatory teams collaborate to provide clients with a fast, efficient, and flexible integrated solution for oligonucleotide development and manufacturing.

Our oligonucleotide platforms are equipped with advanced technologies including GE ÄKTA oligonucleotide solid-phase synthesizer and purification equipment from gram to kg-scale. In addition, analytical equipment including Q-TOF, UPLC-MS, UPLC, GPC, and other instruments can provide support for oligonucleotide structure characterization, analytical method development and validation, final product release testing, and stability research.


Service Offerings

  • Various modified or non-modified antisense oligonucleotides
  • RNAi, RNAa, mRNA
  • Morpholine oligonucleotides
  • Locked oligonucleotides
  • Peptides-oligonucleotide conjugates
  • Self-assembled RNA nanoparticles



  • Integrated experienced team: process development, analytical, manufacturing, QC and QA
  • Well-equipped facilities, high capacity (gram – kilogram scales)
  • Reliable and qualified supply chain management system, including the ability to internally manufacture many key raw materials and intermediates. Learn about our Supply Chain here.
  • Drug Substance and Drug Product manufactured in a single facility to minimize the need for a knowledge transfer between sites when moving from discovery to development to commercialization.
  • GMP compliant manufacturing in an FDA inspected facility  Link to Compliance
  • Adhere to strict EHS compliance
  • Project management system and dedicated team for your individual project
  • Responsiveness and flexibility to change in project needs
  • Competitive lead times
  • Always investing in development and new technologies. Ongoing projects include the implementation of state-of-the-art instrument platforms, novel approaches to chemistry (including liquid phase synthesis) and the latest in conjugation moieties being investigated and used in drug development.
  • Link to brochure